HCPCS Level II code J1670 denotes injection of human tetanus immune globulin up to 250 units, a passive immunization used to provide immediate protection against tetanus following potential exposure. Nationally, this product is clinically important in emergency and ambulatory settings to reduce the risk of tetanus in patients with contaminated wounds or unknown immunization status. Payers commonly cover this injectable under medical benefits when clinically indicated.

This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical role, payer coverage context, and typical sites of service. The publication presents benchmark perspectives, common billing considerations, and any recent policy notices or coding guidance when available. It also clarifies where input data were not provided.

Intended for billing managers, revenue cycle teams, and clinical leaders, the piece explains how J1670 is billed in ambulatory and emergency settings and what information payers typically require for claim adjudication. Data not available in the input are noted where applicable.